The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis

Abstract FOLFIRINOX has been one of the first-line options for advanced pancreatic cancer, even though it induces significant adverse effects. Several institutions have begun using modified FOLFIRINOX to decrease its side effects and increase its tolerability. We systematically investigated the outc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hongxuan Tong, Zhu Fan, Biyuan Liu, Tao Lu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/13b0bd8f9db545da901879f0ffc5158e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:13b0bd8f9db545da901879f0ffc5158e
record_format	dspace
spelling	oai:doaj.org-article:13b0bd8f9db545da901879f0ffc5158e2021-12-02T15:07:44ZThe benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis10.1038/s41598-018-26811-92045-2322https://doaj.org/article/13b0bd8f9db545da901879f0ffc5158e2018-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-26811-9https://doaj.org/toc/2045-2322Abstract FOLFIRINOX has been one of the first-line options for advanced pancreatic cancer, even though it induces significant adverse effects. Several institutions have begun using modified FOLFIRINOX to decrease its side effects and increase its tolerability. We systematically investigated the outcome from patients who initially received modified FOLFIRINOX as a chemotherapy regimen for advanced pancreatic cancer. We used the random-model generic inverse variance method to analyse the binary data with 95% confidence intervals (CIs). Eleven studies were included in the meta-analysis with 563 total patients. The 6-month and 1-year overall survival (OS) rates of locally advanced pancreatic cancer (LAPC) were 90.9% and 76.2%. The 6-month and 1-year progression-free survival (PFS) rates of LAPC were 81.5% and 48.5%. The 6-month and 1-year OS rates of metastatic pancreatic cancer (MPC) were 79.7% and 47.6%. The 6-month and 1-year PFS rates of MPC were 56.3% and 20.6%. The following rates were also calculated: complete response rate (CR): 2.9%; partial response rate (PR): 35.9%; stable disease rate (SD): 41.2%; overall response rate (OR): 34.6%; disease control rate (DCR): 76.7%; progressive disease: 23.1%; and grade III/IV adverse events (AEs): neutropenia 23.1%, febrile neutropenia 4.8%, thrombocytopenia 4.8%, anaemia 5.7%, fatigue 11.5%, nausea 9.1%, diarrhoea 10.1%, vomiting 5.7%, neuropathy 3.8%, and increased ALT 5.7%. In conclusion, modified FOLFIRINOX could provide comparative survival benefits with fewer adverse events compared to the conventional dosage.Hongxuan TongZhu FanBiyuan LiuTao LuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-8 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hongxuan Tong Zhu Fan Biyuan Liu Tao Lu The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis
description	Abstract FOLFIRINOX has been one of the first-line options for advanced pancreatic cancer, even though it induces significant adverse effects. Several institutions have begun using modified FOLFIRINOX to decrease its side effects and increase its tolerability. We systematically investigated the outcome from patients who initially received modified FOLFIRINOX as a chemotherapy regimen for advanced pancreatic cancer. We used the random-model generic inverse variance method to analyse the binary data with 95% confidence intervals (CIs). Eleven studies were included in the meta-analysis with 563 total patients. The 6-month and 1-year overall survival (OS) rates of locally advanced pancreatic cancer (LAPC) were 90.9% and 76.2%. The 6-month and 1-year progression-free survival (PFS) rates of LAPC were 81.5% and 48.5%. The 6-month and 1-year OS rates of metastatic pancreatic cancer (MPC) were 79.7% and 47.6%. The 6-month and 1-year PFS rates of MPC were 56.3% and 20.6%. The following rates were also calculated: complete response rate (CR): 2.9%; partial response rate (PR): 35.9%; stable disease rate (SD): 41.2%; overall response rate (OR): 34.6%; disease control rate (DCR): 76.7%; progressive disease: 23.1%; and grade III/IV adverse events (AEs): neutropenia 23.1%, febrile neutropenia 4.8%, thrombocytopenia 4.8%, anaemia 5.7%, fatigue 11.5%, nausea 9.1%, diarrhoea 10.1%, vomiting 5.7%, neuropathy 3.8%, and increased ALT 5.7%. In conclusion, modified FOLFIRINOX could provide comparative survival benefits with fewer adverse events compared to the conventional dosage.
format	article
author	Hongxuan Tong Zhu Fan Biyuan Liu Tao Lu
author_facet	Hongxuan Tong Zhu Fan Biyuan Liu Tao Lu
author_sort	Hongxuan Tong
title	The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis
title_short	The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis
title_full	The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis
title_fullStr	The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis
title_full_unstemmed	The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis
title_sort	benefits of modified folfirinox for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/13b0bd8f9db545da901879f0ffc5158e
work_keys_str_mv	AT hongxuantong thebenefitsofmodifiedfolfirinoxforadvancedpancreaticcanceranditsinducedadverseeventsasystematicreviewandmetaanalysis AT zhufan thebenefitsofmodifiedfolfirinoxforadvancedpancreaticcanceranditsinducedadverseeventsasystematicreviewandmetaanalysis AT biyuanliu thebenefitsofmodifiedfolfirinoxforadvancedpancreaticcanceranditsinducedadverseeventsasystematicreviewandmetaanalysis AT taolu thebenefitsofmodifiedfolfirinoxforadvancedpancreaticcanceranditsinducedadverseeventsasystematicreviewandmetaanalysis AT hongxuantong benefitsofmodifiedfolfirinoxforadvancedpancreaticcanceranditsinducedadverseeventsasystematicreviewandmetaanalysis AT zhufan benefitsofmodifiedfolfirinoxforadvancedpancreaticcanceranditsinducedadverseeventsasystematicreviewandmetaanalysis AT biyuanliu benefitsofmodifiedfolfirinoxforadvancedpancreaticcanceranditsinducedadverseeventsasystematicreviewandmetaanalysis AT taolu benefitsofmodifiedfolfirinoxforadvancedpancreaticcanceranditsinducedadverseeventsasystematicreviewandmetaanalysis
_version_	1718388433369432064

The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis

Ejemplares similares